Monday, May 20, 2019 9:47:25 AM
is going to be with pharma.There is no doubt what AURORA is focused on.
Here is yet more proof of the potential of CBD's in the health industry.
Is CBD Better Than Big Pharma? Patients Seem to Think So. Image credit: Tinnakorn Jorruang | Getty Images
May 1, 2019 3 min read
It is no secret that Americans are overmedicated. According to one 2017 study, approximately 55 percent of Americans take prescription medications regularly. Of those who take prescription medication, 53 percent get their medicine from more than one healthcare provider, which increases the risk of adverse side effects.
With the advent of cannabidiol (CBD) as a form of medication, many are wondering whether it might serve as the solution to America’s pharmaceutical blues. Here’s a quick rundown on why CBD just might be better than Big Pharma.
What patients say about CBD.
Partnering with HelloMD, the data research firm Brightfield Group conducted an in-depth survey of over 2,400 patients comparing CBD to pharmaceuticals. When asked about the effectiveness of CBD compared to pharmaceuticals, approximately 60 percent of respondents said that, to some extent, CBD was more effective than the prescription medications they had tried or used regularly. Another 75 percent of respondents said that CBD was more effective than over-the-counter remedies.
CBD side effects vs. pharmaceutical side efffects.
If you’ve ever seen a commercial for pharmaceutical drugs, then you are no doubt familiar with the comically long list of side effects that are often quickly repeated at the end of the ad. Without a doubt, many pharmaceutical drugs often come with side effects that are worse than the condition they are treating. Take the anti-inflammatory medication Celebrex for example.
Side effects for Celebrex include: increased risk of heart attack or stroke, serious (and sometimes fatal) bleeding from the stomach and intestines, stomach/abdominal pain, vomiting, chest/jaw/left arm pain, shortness of breath, unusual sweating, weakness on one side of the body, sudden vision changes and slurred speech.
CBD, which is often used as an anti-inflammatory, carries none of these side effects. At its worst, the side effects of CBD include minor complications like nausea, fatigue and irritability. That’s it. No bleeding, no heart attacks, no slurred speech. Comparatively speaking, that is a small price to pay for better health.
The cost of CBD vs. the cost of pharmaceuticals.
It is well documented that patients in the United States pay more for medication than any other developed nation in the world. On average, Americans spend $1,200 per year for prescription medication -- but sometimes it’s much more.
Using Celebrex as an example once again, let’s compare the cost of pharmaceutical drugs and CBD. On average, a 30-day supply of Celebrex can cost anywhere between $203 to $241, depending on your provider and insurer. Assuming that you are paying on the lower end of the price spectrum, that totals to approximately $2,436 per year.
To contrast, a 30-day supply of MedTerra CBD tincture (1,000 mg) costs $79.95. An entire year’s supply would cost roughly $960. The difference in price between a year’s worth of CBD tincture and a year’s worth of Celebrex is approximately $1,476.
CBD is not a wonder drug that will fix all of your problems. There will always be a need for certain prescription medications, and no one is making the argument that all pharmaceutical drugs are bad. However, when you compare the medical benefits of CBD to pharmaceutical drugs that promise to do that same thing, the clear winner is almost always CBD.
Recent ACB News
- Marijuana Stocks Up After Banking Reform Progress • IH Market News • 04/09/2024 10:05:42 AM
- Aurora Cannabis Commends Germany's Landmark Legalization Achievement • PR Newswire (Canada) • 04/01/2024 11:00:00 AM
- Aurora Cannabis Commends Germany's Landmark Legalization Achievement • PR Newswire (US) • 04/01/2024 11:00:00 AM
- Aurora Cannabis Achieves Australia's TGA GMP Certification, Setting Global Standard for Quality and Compliance • PR Newswire (US) • 03/20/2024 11:15:00 AM
- Aurora Cannabis Achieves Australia's TGA GMP Certification, Setting Global Standard for Quality and Compliance • PR Newswire (Canada) • 03/20/2024 11:15:00 AM
- Aurora Introduces Medical Cannabis Pastilles for Patient Relief in Australia • PR Newswire (Canada) • 03/04/2024 02:42:00 PM
- Aurora Introduces Medical Cannabis Pastilles for Patient Relief in Australia • PR Newswire (US) • 03/04/2024 02:42:00 PM
- Aurora Completes Final Repayment of Convertible Senior Notes Representing ~$465 Million in Total Repayments Since 2021; Cannabis Operations Are Now Debt Free[1] • PR Newswire (Canada) • 02/29/2024 10:00:00 PM
- Aurora Completes Final Repayment of Convertible Senior Notes Representing ~$465 Million in Total Repayments Since 2021; Cannabis Operations Are Now Debt Free[1] • PR Newswire (US) • 02/29/2024 10:00:00 PM
- Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis • PR Newswire (US) • 02/28/2024 12:13:00 PM
- Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis • PR Newswire (Canada) • 02/28/2024 12:11:00 PM
- Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis • PR Newswire (US) • 02/28/2024 12:11:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 12:36:30 PM
- Aurora Cannabis Announces CFO Transition and Completion of Previously Announced Share Consolidation • PR Newswire (Canada) • 02/20/2024 12:00:00 PM
- Aurora Cannabis Announces CFO Transition and Completion of Previously Announced Share Consolidation • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/16/2024 02:49:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 12:23:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 12:10:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 12:07:18 PM
- Aurora Cannabis Announces Fiscal 2024 Third Quarter Results; Generates Record Adjusted EBITDA of $4.3 Million • PR Newswire (Canada) • 02/08/2024 12:00:00 PM
- Aurora Cannabis Announces Fiscal 2024 Third Quarter Results; Generates Record Adjusted EBITDA of $4.3 Million • PR Newswire (US) • 02/08/2024 12:00:00 PM
- Aurora Cannabis Acquires MedReleaf Australia • PR Newswire (US) • 02/08/2024 11:45:00 AM
- Aurora Cannabis Acquires MedReleaf Australia • PR Newswire (Canada) • 02/08/2024 11:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:25:23 PM
- Aurora Cannabis Provides Business Update and Announces Date of Third Quarter Fiscal Year 2024 Investor Conference Call • PR Newswire (Canada) • 01/31/2024 12:00:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM